GlaxoSmithKline plc (ADR)  

(Public, NYSE:GSK)   Watch this stock  
Find more results for GSK
+0.28 (0.69%)
Nov 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 40.94 - 41.16
52 week 37.24 - 49.08
Open 41.03
Vol / Avg. 1.56M/3.84M
Mkt cap 100.79B
P/E 6.67
Div/yield 0.58/5.96
EPS 6.14
Shares 4.87B
Beta 0.86
Inst. own 5%
Feb 3, 2016
Q4 2015 GlaxoSmithKline PLC Earnings Release Add to calendar
Nov 10, 2015
GlaxoSmithKline PLC at Credit Suisse Healthcare Conference
Nov 3, 2015
GlaxoSmithKline PLC R&D Meeting
Oct 28, 2015
Q3 2015 GlaxoSmithKline PLC Earnings Call
Oct 28, 2015
Q3 2015 GlaxoSmithKline PLC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 10.56% 12.31%
Operating margin 16.70% 15.64%
EBITD margin - 28.70%
Return on average assets 4.84% 6.84%
Return on average equity 35.23% 48.95%
Employees 98,702 -
CDP Score - 96 B


980 Great West Road
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSK's Vaccines has a portfolio of over 30 paediatric, adolescent, adult travel vaccines. GSK's Established Products Portfolio includes over 50 off-patent products, as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories, such as wellness, oral health, nutrition and skin health. Its brands include Sensodyne, Panadol, Horlicks, Polident, Paradontax, Tums, ENO, NiQuitin/Nicorette, Abreva, Zovirax and Aquafresh. It operates in the United Kingdom, the United States, Belgium and China.

Officers and directors

Andrew Philip Witty Chief Executive Officer, Executive Director
Age: 50
Bio & Compensation  - Reuters
Simon Dingemans Chief Financial Officer, Executive Director
Age: 51
Bio & Compensation  - Reuters
Moncef Slaoui Chairman - Global Vaccines, Executive Director
Age: 55
Bio & Compensation  - Reuters
Roger Connor President - Global Manufacturing & Supply
Bio & Compensation  - Reuters
Abbas Hussain President, Global Pharmaceuticals
Bio & Compensation  - Reuters
Shah Abbas Hussain President - Europe, Japan & EMAP
Age: 49
Bio & Compensation  - Reuters
Patrick Vallance President - Pharmaceuticals R&D
Bio & Compensation  - Reuters
Emma Walmsley President - Consumer Healthcare Worldwide
Bio & Compensation  - Reuters
Daniel Troy Senior Vice President, General Counsel
Bio & Compensation  - Reuters
Claire Thomas Senior Vice President - Human Resources
Bio & Compensation  - Reuters